On Monday, Novo Nordisk A/S NVO introduced its popular weight loss drug Wegovy (semaglutide injection) in the U.K., making it accessible through the National Health Service (NHS) weight management scheme for free prescriptions and in the private market.
However, the company has acknowledged that supply constraints will persist in the foreseeable future.
Some doctors express discomfort about Wegovy's private availability when substantial demand exists within the NHS.
Obesity rates in the U.K. are among the highest in Europe, with significant disparities between more affluent and less affluent areas.
Access to specialist weight management services within the NHS is limited, and individuals facing socioeconomic or language barriers may find it challenging to access these services.
The implications of Wegovy being available privately, alongside its availability through the NHS, remain unclear.
Novo Nordisk is actively working to persuade European governments and insurers to reimburse Wegovy, positioning it as more than just a lifestyle drug.
In the US, Wegovy is priced at $1,350 per month, while in Europe, it retails for approximately €170-€300 per month. British insurers have indicated that they will not cover Wegovy under their policies.
"We are closely monitoring Wegovy demand and are working with regulators and providers to ensure people living with obesity can have access to and remain on treatment," the company added.
Price Action: NVO shares are up 0.94% at $191.09 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
